We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Seagen Inc | NASDAQ:SGEN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 228.74 | 228.74 | 228.74 | 0 | 01:00:00 |
From Nov 2023 to May 2024
By Colin Kellaher
Pfizer has won all regulatory approvals for its $43 billion acquisition of biotech cancer specialist Seagen and expects to seal the deal on Thursday.
New York drugmaker Pfizer on Tuesday said the U.S. antitrust waiting period for the deal has expired, and that it has agreed to irrevocably donate the rights of royalties from U.S. sales of the cancer drug Bavencio to the American Association for Cancer Research to address concerns raised by the Federal Trade Commission.
Pfizer in March agreed to pay $229 a share in cash for Seagen, but the deal drew extra scrutiny from antitrust regulators, including requests in July by the FTC for additional information.
Pfizer said it plans to hold a conference call on Wednesday to discuss the Seagen acquisition and provide full-year 2024 financial guidance.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 12, 2023 07:28 ET (12:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Seagen Chart |
1 Month Seagen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
